nirmatrelvir

PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) .

Nirmatrelvir-D9 is a deuterated compound of Nirmatrelvir. Nirmatrelvir (T9351) has a CAS number of 2628280-40-8. PF-07321332 is a potent and orally active inhibitor of SARS-CoV 3C-like protease (3CLPRO) .

SARS-CoV-2-IN-100 (Compound 172) is a broad-spectrum antiviral agent against various SARS-CoV-2 variants. It works synergistically with Nirmatrelvir to reduce the risk of antiviral resistance.

Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC50 = 0.13 µM, Ki = 8.8 nM). It demonstrates potent inhibitory effects against SARS-CoV-2 variants and Nirmatrelvir-resistant mutants. Jun13296 reduces lung viral titers and prevents lung tissue damage in SARS-CoV-2 infection models.

MPD2 is a PROTAC compound based on a Cereblon-binding ligand that degrades the main protease MPro of SARS-CoV-2. In 293T cells, it effectively reduces MPro protein levels with a DC50 of 296 nM and shows time-dependent activity. MPD2 exhibits strong antiviral properties against various SARS-CoV-2 strains and has increased potency against Nirmatrelvir-resistant variants. It holds potential for researching SARS-CoV-2 diseases.

YL1004 is a potent, selective, and orally effective non-covalent inhibitor that targets the SARS-CoV-2 papain-like protease (PLpro). It has an IC50 of 17.5 nM and a Ki of 2.3 nM against PLpro, with an in vitro anti-SARS-CoV-2 EC50 ranging from 0.08 μM to 1.37 μM. YL1004 inhibits the proteolytic activity of PLpro and blocks its deubiquitination and de-ISGylation activities, thereby restoring the host's innate antiviral immune signaling pathways. It effectively inhibits the replication of SARS-CoV-2 wild type, Delta variant, Omicron variant, and nirmatrelvir-resistant strains. YL1004 is applicable for research on COVID-19 (SARS-CoV-2 infection).